8

Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal

  • Upload
    others

  • View
    2

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal
Page 2: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal
Page 3: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal
Page 4: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal
Page 5: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal
Page 6: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal
Page 7: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal
Page 8: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal